Explore Thymosin Alpha-1 dosage trends, reconstitution volumes, and vial size patterns from anonymized WPA peptide calculator sessions.
Thymosin Alpha-1 (Tα1) is a naturally occurring thymic peptide that plays a key role in T-cell differentiation and immune regulation. This data reveals the dose amounts, vial sizes, and bacteriostatic water volumes researchers most commonly select when setting up their Thymosin Alpha-1 reconstitution protocol.
Thymosin Alpha-1 (Tα1) is a 28-amino acid acetylated peptide originally isolated from the bovine thymic extract thymosin fraction 5 by Allan Goldstein's laboratory at the Albert Einstein College of Medicine in 1972, and characterized through subsequent decades of work as the most clinically advanced single peptide in the thymic-extract family. Tα1 acts upstream of T-cell maturation through Toll-like receptor 9 (TLR9) and TLR2 signaling on dendritic cells, driving Th1-skewed cytokine release and CD4+/CD8+ T-cell expansion — a mechanism distinct from the Khavinson short-peptide bioregulators (Vilon, Thymalin, Testagen) that occupy adjacent pages on this site, and distinct again from the Bach/Dardenne thymulin nonapeptide.
Thymosin Alpha-1 (thymalfasin) is a 28-amino-acid immune-modulating peptide most often sourced for immune-support and antiviral research. Sold abroad as the approved drug Zadaxin for chronic hepatitis B and C, it holds FDA orphan-drug designation but no full U.S. approval. It ships as a lyophilized powder you reconstitute with bacteriostatic water before use.
Thymosin alpha-1 signals through Toll-like receptors (particularly TLR-2 and TLR-9) on dendritic cells and monocytes, biasing dendritic-cell maturation toward Th1 polarization, increasing IL-2 and IFN-γ production, and enhancing CD8 cytotoxic-T-cell and natural-killer-cell activity. It does not act as a thymic-hormone replacement; rather, it acts as a pattern-recognition-receptor-mediated immune modulator.
Randomized trials and large registry data support efficacy in chronic hepatitis B (Andreone et al.), chronic hepatitis C combination regimens, and post-vaccine immune response in elderly subjects. During the COVID-19 pandemic, several Chinese cohort studies reported reduced mortality in severe COVID-19 patients treated with thymosin alpha-1 as an adjunct — these were observational and not confirmed in randomized Western trials.
Thymosin Alpha-1 has a reported half-life of ~2 hours, and the dose intervals researchers model most often fall around twice weekly. A short half-life means each dose clears well before the next on a twice-weekly schedule, so there is no plasma buildup; the immune-modulating effect outlasts the blood level. It is catalogued under Recovery Peptides on WPA.
192 Thymosin Alpha-1 reconstitution calculations have been logged by the WPA community. The most common dose entered is 1.5mg (46 calculations). The median dose across all sessions is 1.2mg. The most common bacteriostatic water volume is 2mL. The most popular vial size is 10mg (154 sessions). The most common dosing frequency is 2x/week (13 logged protocols), followed by daily (7x/week) (12).
These figures come from anonymized WPA peptide calculator sessions.
All figures shown are aggregated from anonymized calculator inputs and are provided strictly for independent laboratory research and educational purposes. They are community usage statistics — not dosing recommendations, and not medical advice.